- Home
- MNMD vs MREO Comparison
MNMD vs MREO Comparison
Compare MNMD & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- MREO
- Stock Information
- Founded
- MNMD 2019
- MREO 2015
- Country
- MNMD United States
- MREO United Kingdom
- Employees
- MNMD N/A
- MREO N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- MNMD Health Care
- MREO Health Care
- Exchange
- MNMD Nasdaq
- MREO Nasdaq
- Market Cap
- MNMD 509.2M
- MREO 438.8M
- IPO Year
- MNMD N/A
- MREO N/A
- Fundamental
- Price
- MNMD $9.76
- MREO $1.76
- Analyst Decision
- MNMD Strong Buy
- MREO Strong Buy
- Analyst Count
- MNMD 6
- MREO 5
- Target Price
- MNMD $24.67
- MREO $7.20
- AVG Volume (30 Days)
- MNMD 1.3M
- MREO 4.4M
- Earning Date
- MNMD 07-31-2025
- MREO 08-12-2025
- Dividend Yield
- MNMD N/A
- MREO N/A
- EPS Growth
- MNMD N/A
- MREO N/A
- EPS
- MNMD N/A
- MREO N/A
- Revenue
- MNMD N/A
- MREO N/A
- Revenue This Year
- MNMD N/A
- MREO N/A
- Revenue Next Year
- MNMD N/A
- MREO $51.92
- P/E Ratio
- MNMD N/A
- MREO N/A
- Revenue Growth
- MNMD N/A
- MREO N/A
- 52 Week Low
- MNMD $4.70
- MREO $1.57
- 52 Week High
- MNMD $10.44
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- MNMD 71.46
- MREO 35.35
- Support Level
- MNMD $9.54
- MREO $1.65
- Resistance Level
- MNMD $10.09
- MREO $1.89
- Average True Range (ATR)
- MNMD 0.47
- MREO 0.15
- MACD
- MNMD 0.18
- MREO -0.03
- Stochastic Oscillator
- MNMD 83.89
- MREO 12.84
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).